(Photo by Flickr user frankieleon, used under a Creative Commons license)
WellDoc’s Series B just got closer to $30 million.
The Midtown-based company, which makes an app for managing type 2 diabetes, announced a total of $29.5 million in its Series B on Tuesday. In December, company officials said they raised $22 million, led by Samsung Ventures and Merck Global Health Innovation Fund.
Though the company is not disclosing how much money each investor provided, a new addition is Johnson & Johnson Innovation — the venture arm of the consumer products giant.
Along with the investment, WellDoc’s BlueStar app will be used in products made by LifeScan, a Johnson & Johnson company in the diabetes space. BlueStar will be integrated into LifeScan’s OneTouch digital glucose monitoring system. BlueStar, which is FDA-approved and must be prescribed, is designed to help patients self-manage when they are outside the healthcare system through motivation, education and behavioral coaching in real time.
“This is a very significant step forward for our company and has the potential to make a difference in the lives of millions of people living with this chronic disease,” WellDoc CEO Kevin McRaith said in a statement.
BlueStar is also integrated into Samsung’s S Health.
Money Moves: Baltimore investment updates from Hungry Harvest, T. Rowe Price and Catalent
Here’s why a Baltimore startup built its health benefits app on Salesforce
Maryland residents will soon be able to opt in to Google and Apple’s mobile contact tracing tool
After adding customers and service upgrades, Blackpoint Cyber raises $7M Series B
Sign-up for daily news updates from Technical.ly Baltimore